Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge
نویسنده
چکیده
A tetravalent live attenuated vaccine composed of chimeras of yellow fever 17D and the four dengue viruses (chimeric yellow fever dengue [CYD]) manufactured by Sanofi Pasteur has completed phase III clinical testing in over 35,000 children 2-16 years of age. The vaccine was recently licensed in four countries. During the first 2 years of observation, CYD vaccine efficacy ranged between 30% and 79% in 10 different countries with an overall efficacy of 56.8%. During year 3, there was an overall efficacy against hospitalization of 16.7%, but a relative risk of hospitalization of 1.6 among children younger than 9 years and 4.95 in children 5 years of age and younger. Vaccination of seronegative children resulted in universal broad dengue neutralizing antibody responses, but poor protection against breakthrough dengue cases. Unless proven otherwise, such breakthrough cases in vaccinated subjects should be regarded as vaccine antibody-enhanced (ADE). The provenance of these cases can be studied serologically using original antigenic sin immune responses in convalescent sera. In conventional dengue vaccine efficacy clinical trials, persons vaccinated as seronegatives may be hospitalized with breakthrough ADE infections, whereas in the placebo group, dengue infection of monotypic immunes results in hospitalization. Vaccine efficacy trial design must identify dengue disease etiology by separately measuring efficacy in seronegatives and seropositives. The reason(s) why CYD vaccine failed to raise protective dengue virus immunity are unknown. To achieve a safe and protective dengue vaccine, careful studies of monotypic CYD vaccines in humans should precede field trials of tetravalent formulations.
منابع مشابه
Points for Consideration for dengue vaccine introduction - recommendations by the Dengue Vaccine Initiative.
Dengue is a public health problem in the tropics and subtropics. There are several vaccine candidates in clinical development. However, there may be gaps in the new vaccine introduction after vaccine licensure before it becomes available in developing countries. In anticipation of the first dengue vaccine candidate to be licensed, Dengue Vaccine Initiative (DVI) and, its predecessor, Pediatric ...
متن کاملNext generation dengue vaccines: a review of candidates in preclinical development.
Dengue represents a major public health problem of growing global importance. In the absence of specific dengue therapeutics, strategies for disease control have increasingly focused on the development of dengue vaccines. While a licensed dengue vaccine is not yet available, several vaccine candidates are currently being evaluated in clinical trials and are described in detail in accompanying a...
متن کاملAssessing dengue vaccination impact: Model challenges and future directions.
In response to the sharp rise in the global burden caused by dengue virus (DENV) over the last few decades, the WHO has set out three specific key objectives in its disease control strategy: (i) to estimate the true burden of dengue by 2015; (ii) a reduction in dengue mortality by at least 50% by 2020 (used as a baseline); and (iii) a reduction in dengue morbidity by at least 25% by 2020. Altho...
متن کاملPrevention and Control Policies of Dengue Vectors (Aedes aegypti and albopictus) in Iran
Background and Objective: Dengue fever has become a major public health problem in many world regions due to increased trade, travel, and problems controlling Aedes vectors. This policy brief aims to review, analyze, and present evidence-based policies for dengue prevention and control. Methods: The present research is a compilation of a policy brief in Iran, carried out in 3 stages according ...
متن کاملDengue Vaccine Public Health Impact Evaluation
A number of resources are available which provide an insight on impact evaluation issues that could relate to CYD-TDV implementation. • The article from Lim, et al. “Points for Consideration for dengue vaccine introduction – recommendations by the Dengue Vaccine Initiative Expert Rev Vaccines; 2016 Apr;15 (4):529-38. doi: 10.1586/14760584.2016.1129279”, describes various elements to accelerate ...
متن کامل